Among the CCR5 inhibitors developed so far, maraviroc is the first drug that has been approved by the US FDA for treating patients with R5 HIV-1. Although many CXCR4 inhibitors, some of which are ...
Hosted on MSN3mon
Q&A: Improving liver cancer outcomes through enhanced immunotherapyOur previous reports have focused on the tumor microenvironment in liver cancer, including the role of CXCR4, a receptor for CXCL12, which helps weaken the immune system's ability to fight cancer ...
Cells were pretreated with 20 μg/ml antibody against CXCR4 (30 min at room temperature; PharMingen, San Diego, California), 100 ng/ml pertussis toxin (30 min at 37 °C), 1 μg/ml genistein (20 ...
Exicure (XCUR) announced that the Australian Patent Office has issued Patent No. 2018388302, titled “GPCR Heteromer Inhibitors and Uses ...
The bicyclam AMD3100 is a well-known small molecule CXCR4 antagonist that strongly and specifically inhibits X4 HIV-1 infection. Tetrahydroquinoline-based AMD070 is a potent and specific X4 HIV-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback